— Know what they know.
Not Investment Advice

Financial News

Sentiment -36.4 4579 articles 2229 bullish 1216 bearish Full Index →
GE HealthCare Wins FDA 510(k) Clearance for Photonova Spectr

GE HealthCare Wins FDA 510(k) Clearance for Photonova Spectra PCCT

GEHC gains FDA nod for Photonova Spectra, a next-gen photon-counting CT system to boost diagnostic precision, workflow efficiency and imaging...
GE HealthCare Wins FDA 510(k) Clearance for Photonova Spectr

GE HealthCare Wins FDA 510(k) Clearance for Photonova Spectra PCCT

GEHC gains FDA nod for Photonova Spectra, a next-gen photon-counting CT system to boost diagnostic precision, workflow efficiency and imaging...
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives $53.00 Consensu

vTv Therapeutics Inc. (NASDAQ:VTVT) Receives $53.00 Consensus PT from Brokerages

vTv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the six...
High Tide Inc. (NASDAQ:HITI) Receives $6.13 Consensus Target

High Tide Inc. (NASDAQ:HITI) Receives $6.13 Consensus Target Price from Analysts

High Tide Inc. (NASDAQ:HITI – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the five research...
📰

akoyaGO Names Mark Montoya CEO to Lead Next Era of Technology-Driven Impact

akoyaGO has named Mark Montoya Chief Executive Officer to lead its next phase of growth as foundations increasingly turn to technology to drive...
Conifer Health and Healthcare Systems of America Announce En

Conifer Health and Healthcare Systems of America Announce Enterprise Revenue Cycle Outsourcing Partnership

Multi-year agreement brings advanced technology, operational scale, and performance-driven revenue cycle best practices to hospitals across three...
Amazon Unleashes Zoox Robotaxis In Austin And Miami To Chall

Amazon Unleashes Zoox Robotaxis In Austin And Miami To Challenge Waymo Dominance

Amazon.com Inc’s (NASDAQ:AMZN) Zoox is preparing to expand its robotaxi service to select members of the public in Austin and Miami later this...
📰

Why Boston Scientific's Big Dip Could Be a Bigger Opportunity

Boston Scientific's pending trial results could help to drive sales growth for years to come after lower-than-expected sales forecasts.
Anti-Aging Protein Research Takes a Step Forward with Cell C

Anti-Aging Protein Research Takes a Step Forward with Cell Cloning

Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC, March 24, 2026 /PRNewswire/ -- Equity-Insider.com — A protein called α-Klotho circulating in the...
Board Member At Agilent Technologies Buys $241K of Stock

Board Member At Agilent Technologies Buys $241K of Stock

It was revealed in a recent SEC filing that DOW WILSON, Board Member at Agilent Technologies (NYSE:A) made a noteworthy insider purchase on March...
Eye On Growth: Dr. Scangos Adds $359K Of Agilent Technologie

Eye On Growth: Dr. Scangos Adds $359K Of Agilent Technologies Stock To Portfolio

Dr. Scangos, Director at Agilent Technologies (NYSE:A), reported an insider buy on March 23, according to a new SEC filing. What Happened:...
GIGABYTE AORUS s'associe à VALORANT Esports EMEA

GIGABYTE AORUS s'associe à VALORANT Esports EMEA

GIGABYTE AORUS soutiendra le VALORANT Champions Tour EMEA et le Game Changers EMEA pendant les saisons 2026 et 2027. Le parrainage matériel comprend...
GIGABYTE AORUS Partners with VALORANT Esports EMEA

GIGABYTE AORUS Partners with VALORANT Esports EMEA

GIGABYTE AORUS will support the VALORANT Champions Tour EMEA and Game Changers EMEA during the 2026 and 2027 seasons. The hardware sponsorship...
GIGABYTE AORUS Partners with VALORANT Esports EMEA

GIGABYTE AORUS Partners with VALORANT Esports EMEA

GIGABYTE AORUS will support the VALORANT Champions Tour EMEA and Game Changers EMEA during the 2026 and 2027 seasons. The hardware sponsorship...
Inlyte Energy Collaborates with Ervin Industries to Strength

Inlyte Energy Collaborates with Ervin Industries to Strengthen U.S. Battery Materials Supply Chain

The partnership combines Inlyte's iron battery technology with Ervin's century-old American manufacturer to strengthen domestic energy storage supply...
J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time

J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?

JNJ stock holds strong above key SMAs for 8 months as Innovative Medicine strength, new drugs and MedTech gains fuel momentum despite patent and...
J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time

J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?

JNJ stock holds strong above key SMAs for 8 months as Innovative Medicine strength, new drugs and MedTech gains fuel momentum despite patent and...
J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time

J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?

JNJ stock holds strong above key SMAs for 8 months as Innovative Medicine strength, new drugs and MedTech gains fuel momentum despite patent and...
Broadcom Lands $970 Million Defense Deal To Power Air Force

Broadcom Lands $970 Million Defense Deal To Power Air Force And Space Force Software

Broadcom Inc (NASDAQ:AVGO) is expanding its government and enterprise footprint with new contracts and product launches focused on security and...
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease

FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug

IONS wins FDA priority review for zilganersen in rare Alexander disease, with a Sept. 22, 2026, decision date backed by strong phase III data.
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease

FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug

IONS wins FDA priority review for zilganersen in rare Alexander disease, with a Sept. 22, 2026, decision date backed by strong phase III data.
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease

FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug

IONS wins FDA priority review for zilganersen in rare Alexander disease, with a Sept. 22, 2026, decision date backed by strong phase III data.
APTIM-EnergySolutions JV Awarded Seat on $999M Navy Contract

APTIM-EnergySolutions JV Awarded Seat on $999M Navy Contract for Demolition Work at Hunters Point Naval Shipyard

APTIM Radiological Services will compete for demolition, construction, supervision, and related task orders to facilitate property transfer for...
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease

FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug

IONS wins FDA priority review for zilganersen in rare Alexander disease, with a Sept. 22, 2026, decision date backed by strong phase III data.
📰

Top Analyst Reports for Eli Lilly, RTX & Abbott

Eli Lilly leads top analyst picks as GLP-1 demand, pipeline advances, and global growth momentum drive strong outlook despite rising competition...
📰

Top Analyst Reports for Eli Lilly, RTX & Abbott

Eli Lilly leads top analyst picks as GLP-1 demand, pipeline advances, and global growth momentum drive strong outlook despite rising competition...
IDEMIA Secure Transactions unterstützt Spaniens landesweite

IDEMIA Secure Transactions unterstützt Spaniens landesweite Einführung von Notfallleuchten mit seiner sicheren Konnektivität

COURBEVOIE, Frankreich, 24. März 2026 /PRNewswire/ -- IDEMIA Secure Transactions (IST), ein weltweit führender Anbieter von sicheren...
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Ob

LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Ob

LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Ob

LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Ob

LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week E

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and...
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week E

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and...
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week E

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and...
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week E

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and...
COR to Expand Retina Consultants of America With $1.1B EyeSo

COR to Expand Retina Consultants of America With $1.1B EyeSouth Deal

Cencora is acquiring EyeSouth's retina business for $1.1 billion, expanding its RCA platform to strengthen foothold in the fast-growing eye care...
COR to Expand Retina Consultants of America With $1.1B EyeSo

COR to Expand Retina Consultants of America With $1.1B EyeSouth Deal

Cencora is acquiring EyeSouth's retina business for $1.1 billion, expanding its RCA platform to strengthen foothold in the fast-growing eye care...
COR to Expand Retina Consultants of America With $1.1B EyeSo

COR to Expand Retina Consultants of America With $1.1B EyeSouth Deal

Cencora is acquiring EyeSouth's retina business for $1.1 billion, expanding its RCA platform to strengthen foothold in the fast-growing eye care...
COR to Expand Retina Consultants of America With $1.1B EyeSo

COR to Expand Retina Consultants of America With $1.1B EyeSouth Deal

Cencora is acquiring EyeSouth's retina business for $1.1 billion, expanding its RCA platform to strengthen foothold in the fast-growing eye care...
ISRG's Margins Contract in Q4: Will Tariffs Continue to Hurt

ISRG's Margins Contract in Q4: Will Tariffs Continue to Hurt in 2026?

ISRG records 37% margins despite tariff pressure, using cost efficiencies and recurring revenue strength to offset headwinds and sustain...
ISRG's Margins Contract in Q4: Will Tariffs Continue to Hurt

ISRG's Margins Contract in Q4: Will Tariffs Continue to Hurt in 2026?

ISRG records 37% margins despite tariff pressure, using cost efficiencies and recurring revenue strength to offset headwinds and sustain...
Cardinal Health vs. McKesson: Which Healthcare Giant Is the

Cardinal Health vs. McKesson: Which Healthcare Giant Is the Smarter Bet?

CAH's turnaround gains traction with strong earnings growth and margin expansion, outpacing MCK's steady performance outlook.
Cardinal Health vs. McKesson: Which Healthcare Giant Is the

Cardinal Health vs. McKesson: Which Healthcare Giant Is the Smarter Bet?

CAH's turnaround gains traction with strong earnings growth and margin expansion, outpacing MCK's steady performance outlook.
ISRG's Margins Contract in Q4: Will Tariffs Continue to Hurt

ISRG's Margins Contract in Q4: Will Tariffs Continue to Hurt in 2026?

ISRG records 37% margins despite tariff pressure, using cost efficiencies and recurring revenue strength to offset headwinds and sustain...
« Prev 1 20 21 22 23 24 41 Next »

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms